These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 38805312)
1. Redefining the standard of care for low-grade serous ovarian cancer. Manning-Geist BL; Cantor T; O'Cearbhaill RE; Grisham RN Clin Adv Hematol Oncol; 2024 Jun; 22(5):205-226. PubMed ID: 38805312 [TBL] [Abstract][Full Text] [Related]
2. Molecular changes driving low-grade serous ovarian cancer and implications for treatment. Kelliher L; Yoeli-Bik R; Schweizer L; Lengyel E Int J Gynecol Cancer; 2024 Oct; 34(10):1630-1638. PubMed ID: 38950921 [TBL] [Abstract][Full Text] [Related]
3. Low-grade serous carcinoma: molecular features and contemporary treatment strategies. Angarita AM; Cholakian D; Fader AN Expert Rev Anticancer Ther; 2015; 15(8):893-9. PubMed ID: 26040191 [TBL] [Abstract][Full Text] [Related]
4. Low-grade serous ovarian cancer: State of the science. Slomovitz B; Gourley C; Carey MS; Malpica A; Shih IM; Huntsman D; Fader AN; Grisham RN; Schlumbrecht M; Sun CC; Ludemann J; Cooney GA; Coleman R; Sood AK; Mahdi H; Wong KK; Covens A; O'Malley DM; Lecuru F; Cobb LP; Caputo TA; May T; Huang M; Siemon J; Fernández ML; Ray-Coquard I; Gershenson DM Gynecol Oncol; 2020 Mar; 156(3):715-725. PubMed ID: 31969252 [TBL] [Abstract][Full Text] [Related]
5. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Grisham RN; Slomovitz BM; Andrews N; Banerjee S; Brown J; Carey MS; Chui H; Coleman RL; Fader AN; Gaillard S; Gourley C; Sood AK; Monk BJ; Moore KN; Ray-Coquard I; Shih IM; Westin SN; Wong KK; Gershenson DM Int J Gynecol Cancer; 2023 Sep; 33(9):1331-1344. PubMed ID: 37591609 [TBL] [Abstract][Full Text] [Related]
6. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Gershenson DM; Miller A; Brady WE; Paul J; Carty K; Rodgers W; Millan D; Coleman RL; Moore KN; Banerjee S; Connolly K; Secord AA; O'Malley DM; Dorigo O; Gaillard S; Gabra H; Slomovitz B; Hanjani P; Farley J; Churchman M; Ewing A; Hollis RL; Herrington CS; Huang HQ; Wenzel L; Gourley C Lancet; 2022 Feb; 399(10324):541-553. PubMed ID: 35123694 [TBL] [Abstract][Full Text] [Related]
7. Advances in precision therapy of low-grade serous ovarian cancer: A review. Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365 [TBL] [Abstract][Full Text] [Related]
8. Low grade serous ovarian carcinoma: identifying variations in practice patterns. Siemon J; Gershenson DM; Slomovitz B; Schlumbrecht M Int J Gynecol Cancer; 2019 Jan; 29(1):174-180. PubMed ID: 30640701 [TBL] [Abstract][Full Text] [Related]
10. Low-grade serous ovarian carcinoma: an evolution toward targeted therapy. Voutsadakis IA Int J Gynecol Cancer; 2020 Oct; 30(10):1619-1626. PubMed ID: 31780569 [TBL] [Abstract][Full Text] [Related]
11. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum. Grisham RN; Chui MH Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920 [TBL] [Abstract][Full Text] [Related]
12. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy. Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350 [TBL] [Abstract][Full Text] [Related]
14. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary. Malpica A; Deavers MT Int J Gynecol Pathol; 2011 Nov; 30(6):613-9. PubMed ID: 21979600 [TBL] [Abstract][Full Text] [Related]
15. Low-grade serous ovarian carcinoma: A comprehensive literature review. Goulding EA; Simcock B; McLachlan J; van der Griend R; Sykes P Aust N Z J Obstet Gynaecol; 2020 Feb; 60(1):27-33. PubMed ID: 31849044 [TBL] [Abstract][Full Text] [Related]
16. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Lisio MA; Fu L; Goyeneche A; Gao ZH; Telleria C Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30813239 [TBL] [Abstract][Full Text] [Related]
17. Low-grade Serous Neoplasia of the Female Genital Tract. Folkins AK; Longacre TA Surg Pathol Clin; 2019 Jun; 12(2):481-513. PubMed ID: 31097112 [TBL] [Abstract][Full Text] [Related]
18. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Boyd C; McCluggage WG Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603 [TBL] [Abstract][Full Text] [Related]
19. GATA3 and stemness of high-grade serous ovarian carcinoma: novel hope for the deadliest type of ovarian cancer. El-Arabey AA; Abdalla M; Abd-Allah AR Hum Cell; 2020 Jul; 33(3):904-906. PubMed ID: 32388811 [No Abstract] [Full Text] [Related]
20. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer. Freimund AE; Beach JA; Christie EL; Bowtell DDL Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]